Optimizing combination chemotherapy by controlling drug ratios.
about
Recent Developments in Active Tumor Targeted Multifunctional Nanoparticles for Combination Chemotherapy in Cancer Treatment and ImagingThe Valley of Death in anticancer drug development: a reassessmentRecent progress in the development of polysaccharide conjugates of docetaxel and paclitaxelSynthetic lethality in lung cancer and translation to clinical therapiesLiposomes as nanomedical devicesCombination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivoThe Comparison of MTT and CVS Assays for the Assessment of Anticancer Agent InteractionsPolymeric Nanostructures for Imaging and TherapyEffects of early chemotherapeutic treatment on learning in adolescent mice: implications for cognitive impairment and remediation in childhood cancer survivorsCodelivery of doxorubicin and paclitaxel by cross-linked multilamellar liposome enables synergistic antitumor activity.Delivery of multipurpose prevention drug combinations from electrospun nanofibers using composite microarchitectures.Combinational delivery of hydrophobic and hydrophilic anticancer drugs in single nanoemulsions to treat MDR in cancerNanotechnology in drug delivery and tissue engineering: from discovery to applicationsSynergistic interactions of the anti-casein kinase 2 CIGB-300 peptide and chemotherapeutic agents in lung and cervical preclinical cancer models.Nanoparticles with Precise Ratiometric Co-Loading and Co-Delivery of Gemcitabine Monophosphate and Cisplatin for Treatment of Bladder Cancer.The effect of co-delivery of paclitaxel and curcumin by transferrin-targeted PEG-PE-based mixed micelles on resistant ovarian cancer in 3-D spheroids and in vivo tumors.Computational analysis of image-based drug profiling predicts synergistic drug combinations: applications in triple-negative breast cancerTreatment of colorectal cancer using a combination of liposomal irinotecan (Irinophore C™) and 5-fluorouracil.Poly(d,l-lactide-co-glycolide)-chitosan composite particles for the treatment of lung cancer.Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in miceEffects of repeated administration of chemotherapeutic agents tamoxifen, methotrexate, and 5-fluorouracil on the acquisition and retention of a learned response in miceEffects of chemotherapeutic agents 5-fluorouracil and methotrexate alone and combined in a mouse model of learning and memory.Rapid optimization of drug combinations for the optimal angiostatic treatment of cancerEfficacy-oriented compatibility for component-based Chinese medicinePharmacokinetic study of 3-in-1 poly(ethylene glycol)-block-poly(D, L-lactic acid) micelles carrying paclitaxel, 17-allylamino-17-demethoxygeldanamycin, and rapamycinSynergistic combinations of multiple chemotherapeutic agents in high capacity poly(2-oxazoline) micellesCombining Oxymatrine or Matrine with Lamivudine Increased Its Antireplication Effect against the Hepatitis B Virus In Vitro.Enhanced anti-tumour effects of Vinca alkaloids given separately from cytostatic therapies.Cancer therapies utilizing the camptothecins: a review of the in vivo literatureRecent advances of cocktail chemotherapy by combination drug delivery systems.Increased killing of SCCVII squamous cell carcinoma cells after the combination of Pc 4 photodynamic therapy and dasatinib is associated with enhanced caspase-3 activity and ceramide synthase 1 upregulation.Preclinical versus clinical drug combination studies.Preclinical optimization of a broad-spectrum anti-bladder cancer tri-drug regimen via the Feedback System Control (FSC) platform.Use of nanoscale delivery systems to maintain synergistic drug ratios in vivo.Active methods of drug loading into liposomes: recent strategies for stable drug entrapment and increased in vivo activity.Nanoscale particulate systems for multidrug delivery: towards improved combination chemotherapy.Novel formulation of cytarabine and daunorubicin: A new hope in AML treatment.Review peptide-targeted liposomes for selective drug delivery: Advantages and problematic issues.Nanoparticle-mediated co-delivery of chemotherapeutic agent and siRNA for combination cancer therapy.Anticancer efficacy and toxicokinetics of a novel paclitaxel-clofazimine nanoparticulate co-formulation.
P2860
Q26778234-69F606D3-EF0D-455B-81C4-BCB617FFEBA9Q26861274-8B847266-E3C3-4E48-80D0-C38BA84116D2Q27010654-9D90690D-C762-4EF6-83D2-B28058208282Q28072904-429309D3-6E8F-4635-8F87-A41B148AB6D9Q28088315-8350F3FB-2A84-4781-9DB2-BF916F1FB548Q28476362-C7529B6D-ED13-4D84-B927-A3ECE5B6B46BQ28552284-ED55F11C-55BE-4B6D-8560-79C1B0B07798Q30372383-F985E804-1C59-481F-99FB-2E6FEB6153FEQ30540341-CF9DCDBD-9CE8-451D-A2EB-BC474C11EBB4Q33598842-7528A483-8EA0-41E2-AB23-1E8B36044BD3Q33800752-C104D09E-5B08-41F7-8AD4-DBBA5D0EEBCAQ34089249-BE364113-7AB7-448F-8587-F1A28F4F3097Q34112647-2C8F90B9-ACB0-4983-BDDF-BB82F136DEAFQ34265716-C1336B52-AE42-40C4-8AE6-52A4103DFED1Q34479313-68C938C3-1270-4F54-9F5D-2C127ABF0D1FQ34615075-AB5715B7-93C5-4866-A38A-94706329E294Q34618624-98ED4A53-1156-4A09-83D6-675A0FB8C7FCQ34693012-EEBB84C4-09DD-4E31-AA93-C2633FBA15BAQ35524032-6BA4964A-9D7F-439B-AD41-A7055CE15932Q35556561-330B4B7A-1FEC-40BF-AC75-76FB062732CCQ35644334-12DD8064-D972-40FB-BA8D-9D0B9CEC2A73Q35686715-9C27E6CB-75C6-4763-81AC-C0F514B58725Q35757208-24649D73-BA82-4CEB-90C9-E78F9639AC6FQ36123992-3A74B372-E891-461F-9093-29C4771DD6E2Q36174463-340CF1F1-9625-463A-9423-D0D5ED157AF5Q36501393-40352AA7-55A0-449E-8E05-B78FDB092FACQ36587237-5429767B-A25D-4270-AB96-E6204CB85791Q36709220-C6DFC314-F6C3-4531-9A84-CC90C8CC3475Q37069556-FBD31EC7-2B42-4713-A8C7-28435556510FQ37206908-45313CAE-1D73-4BF0-AC7E-FD7A510906D8Q37326151-8E9D9D52-4981-493E-A7F3-A0EEE68564C4Q37330186-1261796F-3F98-4192-B8F9-D678B840BE85Q37502313-8843BCE0-49B0-464F-B192-2872DFEDA556Q37813687-FD6C53B1-F5EE-4FB5-A17E-614E02B07DACQ37865021-DC2654AB-2067-4BC8-9ED6-2C0F2E00664CQ38183852-4EF40DB4-71E1-4B6A-B176-BD6F61021390Q38403675-D977B5EC-9686-48EE-94C1-0FD4AD0EE997Q38502588-8D85A2E8-5D75-422D-8564-3C421A028BA9Q38874499-FA68B97A-36F3-4620-B927-CAE701755D2EQ38896952-CD2A0D63-A48D-4686-BD55-DB274778538B
P2860
Optimizing combination chemotherapy by controlling drug ratios.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Optimizing combination chemotherapy by controlling drug ratios.
@en
type
label
Optimizing combination chemotherapy by controlling drug ratios.
@en
prefLabel
Optimizing combination chemotherapy by controlling drug ratios.
@en
P356
P1476
Optimizing combination chemotherapy by controlling drug ratios.
@en
P2093
Andrew S Janoff
Lawrence D Mayer
P304
P356
10.1124/MI.7.4.8
P577
2007-08-01T00:00:00Z